Beijing-based Healthstar Medical Development Co., Ltd (SHA: 603590) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for KC1036 in combination with a programmed-death 1 (PD-1) inhibitor as first-line maintenance therapy for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
KC1036, a tyrosine kinase inhibitor (TKI) that targets AXL, VEGFR2, and FLT3, is currently under investigation in multiple clinical studies for digestive system tumors and thymic tumors. Clinical data to date indicates that KC1036 exhibits significant anti-tumor activity and a favorable safety profile.- Flcube.com
